Results 221 to 230 of about 222,862 (245)
Some of the next articles are maybe not open access.
Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel.
International Journal of Oncology, 1998Our study was designed to evaluate the pharmacokinetics, tissue distribution, toxicity and therapeutic efficacy of liposome-encapsulated paclitaxel (LET) in comparison to conventional paclitaxel. In normal mice, LET was much less toxic than the conventional drug. A dose of 32.5 mg/kg of conventional paclitaxel administered i.v.
Prafulla C. Gokhale +4 more
openaire +2 more sources
Paclitaxel and its formulations
International Journal of Pharmaceutics, 2002Paclitaxel (Taxol) is a promising anti-tumor agent with poor water solubility. It is effective for various cancers especially ovarian and breast cancer. Intravenous administration of a current formulation in a non-aqueous vehicle containing Cremophor EL may cause allergic reactions and precipitation on aqueous dilution. Moreover, the extensive clinical
Alka Garg +2 more
openaire +3 more sources
International Journal of Pharmaceutics, 1999
While the search for new antineoplastic agents is in progress, optimization of delivery for existing drugs will remarkably improve the current scenario in the management of cancer. Paclitaxel, a new antineoplastic agent, is one such drug deserving attention in the field of regional drug delivery, offering immense pharmacokinetic as well as therapeutic ...
Anand Babu Dhanikula, Ramesh Panchagnula
openaire +3 more sources
While the search for new antineoplastic agents is in progress, optimization of delivery for existing drugs will remarkably improve the current scenario in the management of cancer. Paclitaxel, a new antineoplastic agent, is one such drug deserving attention in the field of regional drug delivery, offering immense pharmacokinetic as well as therapeutic ...
Anand Babu Dhanikula, Ramesh Panchagnula
openaire +3 more sources
Liposomal paclitaxel formulations
Journal of Controlled Release, 2012Over the past three decades, taxanes represent one of the most important new classes of drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer drug approved for the treatment of breast and ovarian cancer. However, notwithstanding a suitable premedication, present-day chemotherapy employing a commercial preparation ...
Jaroslav Turánek, Štěpán Koudelka
openaire +3 more sources
Clinical Pharmacokinetics of Paclitaxel
Clinical Pharmacokinetics, 1994Paclitaxel is a new anticancer agent showing significant promise as therapy for solid tumours and leukaemia, given alone or in combination with other chemotherapeutic agents. Paclitaxel concentrations in biological specimens can be measured using high performance liquid chromatography, or more recently by immunoassay.
Daryl Sonnichsen +3 more
openaire +3 more sources
Future Cardiology, 2006
Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells.
Simon Corbett +3 more
openaire +3 more sources
Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells.
Simon Corbett +3 more
openaire +3 more sources
Cancer Investigation, 1997
We appreciate Mr. Hill's comments (Cancer Investigation 14(6):644, 1996) concerning the listing of hypertension in the manufacturer's insert for paclitaxel. We made reference to the (since revised) 1993 insert in our original report because, when it was accepted for publication, that was the current version.
Dominic A. Solimando, Raymond B. Weiss
openaire +2 more sources
We appreciate Mr. Hill's comments (Cancer Investigation 14(6):644, 1996) concerning the listing of hypertension in the manufacturer's insert for paclitaxel. We made reference to the (since revised) 1993 insert in our original report because, when it was accepted for publication, that was the current version.
Dominic A. Solimando, Raymond B. Weiss
openaire +2 more sources
Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer
Seminars in Oncology, 2003The combination of gemcitabine and paclitaxel in metastatic breast cancer is attractive because of the good single-agent activity of each, the different mechanisms of antitumor effect, and the, generally, nonoverlapping toxicity profiles of the agents.
openaire +3 more sources
Overview of Paclitaxel (TAXOL®)
Seminars in Oncology Nursing, 1993The history of development of paclitaxel (TAXOL [Bristol-Myers Squibb Co., Princeton, NJ]) is a long story and serves as a model of perseverance for those involved in drug development. Notations of the use of products of the yew tree date back to the Celts, but it was in the 1950s to the 1960s that the National Cancer Institute (NCI) selected the ...
openaire +3 more sources
Individualized pharmacotherapy with paclitaxel
Current Opinion in Oncology, 2007More than two decades of clinical experience with paclitaxel as an anticancer drug have contributed significantly to the optimization of today's application schemes and patients' safety. Recent knowledge about interindividual pharmacokinetic variability and population modeling provides a novel scientific basis for an improved and individualized ...
openaire +3 more sources